Literature DB >> 7276162

Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap.

T Mimori, M Akizuki, H Yamagata, S Inada, S Yoshida, M Homma.   

Abstract

Autoantibodies in the serum from a patient with connective tissue disease have been used to define a high molecule weight acidic nuclear protein antigen. The antigen tentatively termed Ku, after the first two letters of patient's name, has distinct physicochemical properties and immunological specificities that distinguish it from previously reported antigens. The Ku antigen has an apparent 300,000 mol wt as determined by gel filtration and sucrose density gradient ultracentrifugation techniques. The antigen is destroyed by trypsin, mild heating, and pH variations greater than 10 and less than 5. Treatment with ribonuclease or deoxyribonuclease did not affect the antigenic reactivity. The Ku antigen was demonstrated in the soluble extracts of human, calf, and rabbit, but not of rat tissues. Purified antibody localized the Ku antigen within the nuclei of human liver where a "reticular" pattern of immunofluorescence was seen. Of 330 patients with various connective tissue diseases, 9 had precipitating antibodies to the Ku antigen. Preliminary results of clinical analysis indicated that antibody to the Ku antigen might become a useful marker for a group of patients with clinical characteristics of both polymyositis and scleroderma with a good prognosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7276162      PMCID: PMC370841          DOI: 10.1172/jci110295

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Determination of nucleic acids in animal tissues.

Authors:  G CERIOTTI
Journal:  J Biol Chem       Date:  1955-05       Impact factor: 5.157

2.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

3.  Metabolism of autologous and homologous IgG in rheumatoid arthritis.

Authors:  M A Catalano; E H Krick; D H De Heer; R M Nakamura; A N Theofilopoulos; J H Vaughan
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

4.  Anti-tissue antibodies in rheumatic disease: standardization and nomenclature.

Authors:  E M Tan; C Christian; H R Holman; M Homma; H G Kunkel; M Reichlin; G C Sharp; M Ziff; E V Barnett
Journal:  Arthritis Rheum       Date:  1977 Sep-Oct

5.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

Authors:  A S Douvas; M Achten; E M Tan
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

6.  Purification and characterization of a nuclear non-histone basic protein (Mi-1) which reacts with anti-immunoglobulin sera and the sera of patients with dermatomyositis.

Authors:  M Nishikai; M Reichlin
Journal:  Mol Immunol       Date:  1980-09       Impact factor: 4.407

7.  Antibody to a soluble acidic nuclear antigen in Sjögren's syndrome.

Authors:  S S Kassan; M Akizuki; A D Steinberg; R L Reddick; T M Chused
Journal:  Am J Med       Date:  1977-09       Impact factor: 4.965

8.  Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system.

Authors:  M Nishikai; M Reichlin
Journal:  Arthritis Rheum       Date:  1980-08

9.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06

10.  A soluble acidic protein of the cell nucleus which reacts with serum from patients with systemic lupus erythermatosus and Sjögren's syndrome.

Authors:  M Akizuki; R Powers; H R Holman
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

View more
  91 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

2.  Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin.

Authors:  M Kubo; H Ihn; M Kuwana; K Yamane; N Yazawa; K Tamaki
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 3.  B-cell epitopes of autoantigenic DNA-binding proteins.

Authors:  C H Chou; M Satoh; J Wang; W H Reeves
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 4.  B-cell epitopes of scleroderma-specific autoantigens.

Authors:  R Verheijen
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

5.  Ku autoantigen is the regulatory component of a template-associated protein kinase that phosphorylates RNA polymerase II.

Authors:  A Dvir; S R Peterson; M W Knuth; H Lu; W S Dynan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  Cell surface expression of the 70-kD component of Ku, a DNA-binding nuclear autoantigen.

Authors:  B S Prabhakar; G P Allaway; J Srinivasappa; A L Notkins
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

7.  Coilin interacts with Ku proteins and inhibits in vitro non-homologous DNA end joining.

Authors:  Venkatramreddy Velma; Zunamys I Carrero; Angela M Cosman; Michael D Hebert
Journal:  FEBS Lett       Date:  2010-11-09       Impact factor: 4.124

8.  Role of antigen selectivity in autoimmune responses to the Ku (p70/p80) antigen.

Authors:  W H Reeves; Z M Sthoeger; R G Lahita
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

9.  The nucleotide sequence of a mouse cDNA encoding the 80 kDa subunit of the Ku (p70/p80) autoantigen.

Authors:  M Falzon; E L Kuff
Journal:  Nucleic Acids Res       Date:  1992-07-25       Impact factor: 16.971

Review 10.  The Ku autoantigen: cast in a new light.

Authors:  A Robinson
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.